NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it made further steps towards centralized current good manufacturing practice (“cGMP”) manufacturing of its lead drug candidate Iomab™-B. The Company engaged IBA Molecular North America, Inc. to scale up under cGMPs, the production of Iomab™-B and further develop and validate the quality control testing of the product.
Help employers find you! Check out all the jobs and post your resume.
